Table 1.

Trials of first-line EGFR-TKI therapy included in this study

Trial/AuthorPatient selectionDrug1st-line pts treated, n1st-line pts tested for EGFR, n1st-line pts tested for KRAS, n
Giaccone et al. (1)UnselectedErlotinib532826
Jackman et al. (2)Patients ≥ age 70 yErlotinib804341
Miller et al. (3)Adenocarcinoma with BAC featuresErlotinib755756
Sequist et al. (4)Known EGFR mutationsGefitinib31310
Jackman et al. (5)Women, adenocarcinoma, not current smokersErlotinib786352

Abbreviations: pts, patients; BAC, bronchioloalveolar carcinoma.